Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report

In the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS) p.G12C mutation. However, patients with untreated and/or active brain metastases were excluded from the trial, and th...

Full description

Bibliographic Details
Main Authors: Alessandro Inno, Fabiana Marchetti, Matteo Valerio, Niccolò Giaj Levra, Filippo Alongi, Giovanni Foti, Stefania Gori
Format: Article
Language:English
Published: AboutScience Srl 2023-06-01
Series:Drug Target Insights
Subjects:
Brain metastases
Central nervous system
KRAS
NSCLC
Sotorasib
Online Access:https://journals.aboutscience.eu/index.php/dti/article/view/2593

Internet

https://journals.aboutscience.eu/index.php/dti/article/view/2593

Similar Items